These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 15225099)

  • 1. Applicability of biomarkers in the early diagnosis of prostate cancer.
    Hessels D; Verhaegh GW; Schalken JA; Witjes JA
    Expert Rev Mol Diagn; 2004 Jul; 4(4):513-26. PubMed ID: 15225099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression analysis of delta-catenin and prostate-specific membrane antigen: their potential as diagnostic markers for prostate cancer.
    Burger MJ; Tebay MA; Keith PA; Samaratunga HM; Clements J; Lavin MF; Gardiner RA
    Int J Cancer; 2002 Jul; 100(2):228-37. PubMed ID: 12115574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular prostate cancer pathology: current issues and achievements.
    Schalken JA; Bergh A; Bono A; Foster C; Gospadarowicz M; Isaacs WB; Rubin M; Schröder F; Tribukait B; Tsukamotot T; Wiklund P
    Scand J Urol Nephrol Suppl; 2005 May; (216):82-93. PubMed ID: 16019760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary biomarkers for prostate cancer: a review.
    Hessels D; Schalken JA
    Asian J Androl; 2013 May; 15(3):333-9. PubMed ID: 23524531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical applications of molecular biomarkers in prostate cancer detection.
    Dumache R; Miclea F; Bumblăcilă B; Puiu M
    Rev Med Chir Soc Med Nat Iasi; 2010; 114(2):470-5. PubMed ID: 20700989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimization of prostate cancer cell detection using multiplex tyramide signal amplification.
    Roy S; Axelrod HD; Valkenburg KC; Amend S; Pienta KJ
    J Cell Biochem; 2019 Apr; 120(4):4804-4812. PubMed ID: 30390333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased expression of delta-catenin/neural plakophilin-related armadillo protein is associated with the down-regulation and redistribution of E-cadherin and p120ctn in human prostate cancer.
    Lu Q; Dobbs LJ; Gregory CW; Lanford GW; Revelo MP; Shappell S; Chen YH
    Hum Pathol; 2005 Oct; 36(10):1037-48. PubMed ID: 16226102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Related biomarkers in the diagnosis of prostate cancer].
    Xu YM; Liu HZ
    Zhonghua Nan Ke Xue; 2015 Oct; 21(10):937-40. PubMed ID: 26665686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarkers for prostate cancer.
    Leman ES; Getzenberg RH
    J Cell Biochem; 2009 Sep; 108(1):3-9. PubMed ID: 19507229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ad5/35E1aPSESE4: A novel approach to marking circulating prostate tumor cells with a replication competent adenovirus controlled by PSA/PSMA transcription regulatory elements.
    Hwang JE; Joung JY; Shin SP; Choi MK; Kim JE; Kim YH; Park WS; Lee SJ; Lee KH
    Cancer Lett; 2016 Mar; 372(1):57-64. PubMed ID: 26723876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitivity of HOXB13 as a Diagnostic Immunohistochemical Marker of Prostatic Origin in Prostate Cancer Metastases: Comparison to PSA, Prostein, Androgen Receptor, ERG, NKX3.1, PSAP, and PSMA.
    Kristiansen I; Stephan C; Jung K; Dietel M; Rieger A; Tolkach Y; Kristiansen G
    Int J Mol Sci; 2017 May; 18(6):. PubMed ID: 28555048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using Genetic and Epigenetic Markers to Improve Differential Diagnosis of Prostate Cancer and Benign Prostatic Hyperplasia by Noninvasive Methods in Mexican Patients.
    Sánchez BE; Aguayo A; Martínez B; Rodríguez F; Marmolejo M; Svyryd Y; Luna L; Muñoz LA; Jiménez MA; Sotomayor M; Vargas V F; Mutchinick OM
    Clin Genitourin Cancer; 2018 Aug; 16(4):e867-e877. PubMed ID: 29571584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New biomarkers in prostate cancer].
    Gao W; Teng LH
    Zhonghua Bing Li Xue Za Zhi; 2013 Jul; 42(7):487-90. PubMed ID: 24246875
    [No Abstract]   [Full Text] [Related]  

  • 14. Advances in biomarkers for the early diagnosis of prostate cancer.
    Cao DL; Yao XD
    Chin J Cancer; 2010 Feb; 29(2):229-33. PubMed ID: 20109357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging biomarkers for the diagnosis and prognosis of prostate cancer.
    Sardana G; Dowell B; Diamandis EP
    Clin Chem; 2008 Dec; 54(12):1951-60. PubMed ID: 18927246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis.
    Bravaccini S; Puccetti M; Bocchini M; Ravaioli S; Celli M; Scarpi E; De Giorgi U; Tumedei MM; Raulli G; Cardinale L; Paganelli G
    Sci Rep; 2018 Mar; 8(1):4254. PubMed ID: 29523813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The utility of PSMA and PSA immunohistochemistry in the cytologic diagnosis of metastatic prostate carcinoma.
    Bernacki KD; Fields KL; Roh MH
    Diagn Cytopathol; 2014 Jul; 42(7):570-5. PubMed ID: 24273068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Updated application of prostate-specific membrane antigen to the diagnosis and treatment of prostate cancer].
    Tang QL; Yao MY
    Zhonghua Nan Ke Xue; 2008 Jan; 14(1):79-82. PubMed ID: 18297820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumour markers for managing men who present with metastatic prostate cancer and serum prostate-specific antigen levels of <10 ng/mL.
    Birtle AJ; Freeman A; Masters JR; Payne HA; Harland SJ;
    BJU Int; 2005 Aug; 96(3):303-7. PubMed ID: 16042718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Global expression of AMACR transcripts predicts risk for prostate cancer - a systematic comparison of AMACR protein and mRNA expression in cancerous and noncancerous prostate.
    Alinezhad S; Väänänen RM; Ochoa NT; Vertosick EA; Bjartell A; Boström PJ; Taimen P; Pettersson K
    BMC Urol; 2016 Feb; 16():10. PubMed ID: 26928323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.